Quick Answer
Tempest Therapeutics, Inc. reported Net Income of -$26.26 million for fiscal year 2025.
Tempest Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$26.26M | +37.2% |
| 2024 | -$41.84M | -41.9% |
| 2023 | -$29.49M | +17.4% |
| 2022 | -$35.71M | -26.2% |
| 2021 | -$28.30M | -47.3% |
| 2020 | -$19.21M | +56.9% |
| 2019 | -$44.57M | -63.9% |
| 2018 | -$27.19M | +67.8% |
| 2017 | -$84.58M | -2.8% |
| 2016 | -$82.26M | -12.3% |
| 2015 | -$73.22M | -47.9% |
| 2014 | -$49.52M | -70.5% |
| 2013 | -$29.04M | -115.0% |
| 2012 | -$13.51M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.51M | +66.7% | +55.4% |
| June 30, 2025 | -$7.87M | +17.8% | +27.5% |
| March 31, 2025 | -$10.86M | -37.4% | -2.9% |
| September 30, 2024 | -$10.56M | -55.6% | -10.3% |
| June 30, 2024 | -$9.57M | -26.2% | -21.1% |
| March 31, 2024 | -$7.90M | -3.5% | -16.5% |
| September 30, 2023 | -$6.79M | +24.2% | +10.5% |
| June 30, 2023 | -$7.58M | +17.3% | +0.7% |
- Tempest Therapeutics, Inc. showed an increase of +37.2% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Tempest Therapeutics, Inc.’s net income has declined by 94.4% (from -$13.51 million to -$26.26 million).
- The most recent figure is from Tempest Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: